Improved Child Nutrition and Development Through Social Transfers (TENDER)

April 28, 2026 updated by: Jordyn Wallenborn, Swiss Tropical & Public Health Institute

Taabo Enhanced Nutrition and Development Through Economic Rewards

The goal of this clinical trial is to learn if a conditional social transfer works to improve rates of complementary breastfeeding. It will also learn about the impacts of social transfers on maternal and child health and development. The main questions it aims to answer are:

  • Does the social transfer increase complementary breastfeeding rates at 24-months postpartum?
  • Does the social transfer increase complementary breastfeeding duration?
  • Does the social transfer impact child health and development?
  • Does the social transfer impact maternal physical and mental health?

Researchers will compare a conditional social transfer to a control group that only receives education about breastfeeding recommendations to see if a conditional social transfers works to increase complementary breastfeeding.

Participants will:

Receive a pamphlet explaining the current recommendations of breastfeeding Receive instructions that if they meet the recommendation to breastfeed until 24-months postpartum they receive a social transfer or receive no additional information Complete home visits at 12- and 24-months postpartum Complete detailed questionnaire

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

1040

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Are enrolled in the Taabo multigenerational birth cohort (MGC)
  2. Completed the postpartum interview of the Taabo MGC
  3. Have a child who is within two weeks of their 12-month birthday,
  4. are breastfeeding at time of recruitment,
  5. live in the Taabo HDSS, Côte d'Ivoire
  6. have no illnesses that contraindicates breastfeeding,
  7. had a healthy singleton infant with a birth weight of at least 2500 grams, and
  8. agree to participate and sign an informed consent; if underage (12-17 years), a legal representative will also have to agree to sign the informed consent

Exclusion Criteria:

  1. Plans to move permanently outside study area
  2. Has a medical, intellectual or psychological disability
  3. Contraindication for breastfeeding
  4. Children born with < 2500 grams

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Social Transfer
A social transfer is provided at the 24-month visit, conditional on the mother still breastfeeding at the time of the visit. They also receive education about current breastfeeding recommendations.
Other: Social Transfer
A social transfer will be given conditioned upon breastfeeding at 24-months postpartum.
No Intervention: Control
No intervention is provided besides education on current breastfeeding recommendations.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of Complementary Breastfeeding
Time Frame: from 12 to 24 months postpartum
Prevalence of complementary breastfeeding at 24 months postpartum.
from 12 to 24 months postpartum
Complementary Breastfeeding Duration
Time Frame: from 12 to 24 months postpartum
Duration of complementary breastfeeding in weeks.
from 12 to 24 months postpartum

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Weight-for-Age z-score
Time Frame: 12 months; 24 months
Infants will be weighed in kilograms by a mobile weighing scale. Measurements will be analyzed as age standardized z-scores.
12 months; 24 months
Child Health Outcomes
Time Frame: 12 months; 24 months
We will assess the child's health outcomes by using a questionnaire administered to the caregiver. The questionnaire will ask a range of yes or no questions about child diarrhea, respiratory illness, fever, and child antibiotic use.
12 months; 24 months
Percent weight loss
Time Frame: 12 months; 24 months;
Percent weight loss will use body weight (kg) and pregnancy weight of the mother controlling for time of measurement. Percent weight loss will be calculated as ((current weight - pregnancy weight) / pregnancy weight) × 100.
12 months; 24 months;
Mother and Child Hemoglobin Levels
Time Frame: 12 months; 24 months
We will assess the mother and child anemia levels. The HemoCue Hb 301 will be used to give an instant measurement of the Haemoglobin (Hb) level of the patient. Capillary blood will be collected through a finger prick. Blood samples drawn for the haemoglobin assessment will be discarded after the test. Iron levels will be analyzed as a continuous outcome.
12 months; 24 months
Maternal Depression
Time Frame: 12 months; 24 months
Maternal postpartum depression will be assessed using the Patient Health Questionnaire-9 (PHQ-9); categorized as a binary: no depression (score <10) or depression present (score ≥10).
12 months; 24 months
Height-for-age z-score
Time Frame: 12 months; 24 months
Height will be measured in centimeters by using a Height Measuring Device, stadiometer, 20-205cm. All measurements will be analyzed as age standardized z-scores
12 months; 24 months
Mid-upper arm circumference (MUAC)
Time Frame: 12 months; 24 months
Infants will be measured for mid-upper arm circumference (MUAC) using non-stretchable measuring tape. All measurements will be analyzed as age standardized z-scores.
12 months; 24 months
Mother and Child Anemia
Time Frame: 12 months; 24 months
The HemoCue Hb 301 will be used to give an instant measurement of the Haemoglobin (Hb) level of the patient. Capillary blood will be collected through a finger prick. Blood samples drawn for the haemoglobin assessment will be discarded after the test. Hemoglobin levels (gm/dL) will be used to categorize mothers and children into a binary variable: anemic or not anemic.
12 months; 24 months
Maternal weight change
Time Frame: 12 months; 24 months;

Weight weight change will use body weight (kg) and pregnancy weight of the mother controlling for time of measurement. Maternal weight change will be calculated as the difference between postpartum weight and pregnancy weight. Because pregnancy weight varies by gestational age, analyses will control for gestational age at pregnancy weight measurement and time postpartum at outcome measurement.

Categorized as: no weight loss (0 kg); moderate weight loss (<0 to >-5 kg); high weight loss (≥-5 kg); moderate weight gain (>0 to <5 kg); high weight gain (≥5 kg).
12 months; 24 months;
Change in systolic and diastolic blood pressure (mmHg)
Time Frame: 12 months; 24 months;
Change in systolic and diastolic blood pressure (mmHg) from baseline of the mothers will be categorized as low, normal, or high according to standard clinical thresholds.
12 months; 24 months;
Change in systolic and diastolic blood pressure (mmHg)
Time Frame: 12 months; 24 months;
Change in systolic and diastolic blood pressure (mmHg) from baseline of the mothers will be analyzed as a continuous measure.
12 months; 24 months;
Caregiver Reported Early Development Instruments (CREDI) cognitive z-score
Time Frame: 12 months; 24 months
The CREDI long-form will be administered. Raw item data will be converted to norm-referenced z-scores using the CREDI scoring procedure.
12 months; 24 months
CREDI language z-score
Time Frame: 12 months; 24 months
The CREDI long-form will be administered. Raw item data will be converted to norm-referenced z-scores using the CREDI scoring procedure.
12 months; 24 months
CREDI motor z-score
Time Frame: 12 months; 24 months
The CREDI long-form will be administered. Raw item data will be converted to norm-referenced z-scores using the CREDI scoring procedure.
12 months; 24 months
CREDI social-emotional z-score
Time Frame: 12 months; 24 months
The CREDI long-form will be administered. Raw item data will be converted to norm-referenced z-scores using the CREDI scoring procedure.
12 months; 24 months
Maternal Anxiety
Time Frame: 12 months; 24 months
Maternal postpartum anziety will be assessed using the the GAD-7 (Generalized Anxiety Disorder-7); a seven-item self-report questionnaire designed to measure the severity of anxiety; categorized as: Minimal Anxiety: score 0-4; Mild Anxiety: score 5-9; Moderate Anxiety: score 10-14; Severe Anxiety: score 15-21
12 months; 24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Swiss Tropical & Public Health Institute

Collaborators

Centre Suisse de Recherches Scientifique en Côte d'Ivoire

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2026

Primary Completion (Estimated)

February 28, 2028

Study Completion (Estimated)

February 28, 2028

Study Registration Dates

First Submitted

April 15, 2026

First Submitted That Met QC Criteria

April 28, 2026

First Posted (Actual)

May 6, 2026

Study Record Updates

Last Update Posted (Actual)

May 6, 2026

Last Update Submitted That Met QC Criteria

April 28, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025-50

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diarrhea

Clinical Trials on Social Transfer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe